Skip to content
value.today

Biocon Limited: peers

Change the peers

Biocon Limited beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Belite Bio, Inc: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Biocon Limited, Syngene International Limited, Belite Bio, Inc, CG Oncology, Inc., Oruka Therapeutics, Inc., Immunovant, Inc., Alkermes plc., Rhythm Pharmaceuticals, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureBiocon Limitedbase
BIOCON.BO · 🇮🇳 IN
Percentile in Healthcare
Percentile in India
Syngene International Limited
SYNGENE.BO · 🇮🇳 IN
Percentile in Healthcare
Percentile in India
Belite Bio, Inc
BLTE · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
CG Oncology, Inc.
CGON · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Oruka Therapeutics, Inc.
ORKA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Immunovant, Inc.
IMVT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Alkermes plc.
ALKS · 🇮🇪 IE
Percentile in Healthcare
Percentile in Ireland
Rhythm Pharmaceuticals, Inc.
RYTM · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$6.4 BNov 20, 2026 · Market data5th of 8$2.0 BNov 20, 2026 · Market data8th of 8$6.4 BAug 1, 2026 · Market data6th of 8$6.6 BSep 24, 2026 · Market data3rd of 8$6.5 BOct 28, 2026 · Market data4th of 8$6.6 BOct 7, 2026 · Market data2nd of 8$6.7 BOct 14, 2026 · Market data1st of 8$6.0 BOct 15, 2026 · Market data7th of 8$6.5 B8 ranked
Revenue (Better neither way: ranked highest first)——————$4 MFY2025 · SEC3rd of 3————$1.5 BFY2025 · SEC1st of 3$190 MFY2025 · SEC2nd of 3$190 M3 ranked
Net income (Higher is better)————$-78 MFY2025 · SEC2nd of 6$-161 MFY2025 · SEC4th of 6$-105 MFY2025 · SEC3rd of 6$-506 MFY2025 · SEC6th of 6$242 MFY2025 · SEC1st of 6$-197 MFY2025 · SEC5th of 6$-133 M6 ranked
Employees (Better neither way: ranked highest first)12,000As on 2020 · Profile1st of 86,148As on 2020 · Profile2nd of 841December 31, 2025 · Profile8th of 8142December 31, 2025 · Profile5th of 868December 31, 2025 · Profile7th of 870As on 2021 · Profile6th of 82,050February 20, 2026 · Profile3rd of 8414February 1, 2026 · Profile4th of 82788 ranked
Growth
Revenue growth (Higher is better)————————————+254.4%FY2025 · SEC1st of 397th98th————————-5.3%FY2025 · SEC3rd of 318th9th+45.8%FY2025 · SEC2nd of 383rd91st+45.8%3 ranked
Revenue growth, 3 years a year (Higher is better)————————————————————————+9.9%FY2025 · SEC2nd of 253rd82nd+100.2%FY2025 · SEC1st of 295th98th+55.1%2 ranked
Earnings per share growth (Higher is better)————————————————————————-34.1%FY2025 · SEConly one with it14th21st————-34.1%—
Margins and returns
Gross margin (Higher is better)————————————————————————86.7%FY2025 · SEC2nd of 287th97th89.7%FY2025 · SEC1st of 292nd97th88.2%2 ranked
Operating margin (Higher is better)————————————————————————17.2%FY2025 · SEC1st of 285th74th-101.2%FY2025 · SEC2nd of 223rd10th-42.0%2 ranked
Net margin (Higher is better)————————————————————————16.4%FY2025 · SEC1st of 287th91st-103.6%FY2025 · SEC2nd of 222nd9th-43.6%2 ranked
Free cash flow margin (Higher is better)————————————————————————32.5%FY2025 · SEC1st of 297th98th-61.5%FY2025 · SEC2nd of 226th11th-14.5%2 ranked
Return on equity (Higher is better)————————-16.9%FY2025 · SEC2nd of 662nd29th-21.7%FY2025 · SEC3rd of 660th27th-24.7%FY2025 · SEC4th of 658th26th-64.8%FY2025 · SEC5th of 636th15th14.7%FY2025 · SEC1st of 687th64th-244.4%FY2025 · SEC6th of 67th3rd-23.2%6 ranked
Return on invested capital (Higher is better)————————————————————————14.7%FY2025 · SEConly one with it64th55th————14.7%—
Valuation
P/E ratio (Better neither way: ranked highest first)153.9×price Nov 20, 2026 · Market data1st of 293rd95th35.1×price Nov 20, 2026 · Market data2nd of 255th53rd————————————————————————94.5×2 ranked
Price to sales (Better neither way: ranked highest first)3.5×price Nov 20, 2026 · Market data4th of 449th52nd5.1×price Nov 20, 2026 · Market data2nd of 457th62nd————————————————3.8×price Oct 14, 2026 · Market data3rd of 450th79th21.4×price Oct 15, 2026 · Market data1st of 484th94th4.4×4 ranked
Price to book (Better neither way: ranked highest first)1.6×price Nov 20, 2026 · Market data7th of 733rd18th4.5×price Nov 20, 2026 · Market data5th of 764th50th8.3×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price8.7×price Sep 24, 2026 · Market data3rd of 782nd88th13.8×price Oct 28, 2026 · Market data2nd of 789th93rd7.8×price Oct 7, 2026 · Market data4th of 779th86th3.7×price Oct 14, 2026 · Market data6th of 758th62nd43.2×price Oct 15, 2026 · Market data1st of 797th98th7.8×7 ranked
Free cash flow yield (Higher is better)————————-0.6%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-2.0%price Sep 24, 2026 · Market data4th of 562nd32nd-1.4%price Oct 28, 2026 · Market data2nd of 564th34th-6.1%price Oct 7, 2026 · Market data5th of 552nd25th7.2%price Oct 14, 2026 · Market data1st of 592nd62nd-1.9%price Oct 15, 2026 · Market data3rd of 562nd32nd-1.9%5 ranked
Financial strength
Debt to equity (Lower is better)————————————0.0×FY2025 · SEC1st of 35th3rd————————0.0×FY2025 · SEC1st of 35th3rd0.7×FY2025 · SEC3rd of 366th56th0.0×3 ranked
Net debt to EBITDA (Lower is better)————————————————————————-1.4×FY2025 · SEConly one with it11th5th————-1.4×—
Piotroski F-score (Higher is better)——————————————6 of 9FY2025 · SEConly one with it6.0 of 9—
Scorecard
Scorecard (Higher is better)————1 of 8FY2025 · Scorecard4th of 64 of 13FY2025 · Scorecard3rd of 61 of 10FY2025 · Scorecard5th of 61 of 12FY2025 · Scorecard6th of 615 of 24FY2025 · Scorecard1st of 67 of 20FY2025 · Scorecard2nd of 622% passed6 ranked
Valuation checks (Higher is better)——————0 of 4FY2025 · Scorecard2nd of 50 of 4FY2025 · Scorecard2nd of 50 of 4FY2025 · Scorecard2nd of 53 of 6FY2025 · Scorecard1st of 50 of 5FY2025 · Scorecard2nd of 50% passed5 ranked
Growth checks (Higher is better)————0 of 2FY2025 · Scorecard4th of 61 of 2FY2025 · Scorecard2nd of 60 of 1FY2025 · Scorecard4th of 60 of 2FY2025 · Scorecard4th of 62 of 6FY2025 · Scorecard3rd of 63 of 5FY2025 · Scorecard1st of 617% passed6 ranked
Profitability checks (Higher is better)————0 of 3FY2025 · Scorecard3rd of 60 of 2FY2025 · Scorecard3rd of 60 of 3FY2025 · Scorecard3rd of 60 of 3FY2025 · Scorecard3rd of 64 of 6FY2025 · Scorecard1st of 61 of 5FY2025 · Scorecard2nd of 60% passed6 ranked
Financial health checks (Higher is better)————1 of 2FY2025 · Scorecard4th of 63 of 4FY2025 · Scorecard2nd of 61 of 2FY2025 · Scorecard4th of 61 of 2FY2025 · Scorecard4th of 65 of 5FY2025 · Scorecard1st of 63 of 4FY2025 · Scorecard2nd of 663% passed6 ranked
Shareholder returns checks (Higher is better)————0 of 1FY2025 · Scorecard2nd of 50 of 1FY2025 · Scorecard2nd of 5——0 of 1FY2025 · Scorecard2nd of 51 of 1FY2025 · Scorecard1st of 50 of 1FY2025 · Scorecard2nd of 50% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)————23.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 6104.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 6113.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 652.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 6104.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 6114.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 6104.2%6 ranked
Institutions holding (Better neither way: ranked highest first)————962026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 62332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 62592026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 62322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 64162026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 63332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 62466 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——————+1.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 5+24.3 pp2026-Q2 against 2026-Q1 · 13F1st of 5-0.8 pp2026-Q2 against 2026-Q1 · 13F5th of 5+0.7 pp2026-Q2 against 2026-Q1 · 13F4th of 5+5.1 pp2026-Q2 against 2026-Q1 · 13F2nd of 5+1.2 pp5 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Biocon Limited: National Stock Exchange of India, daily market-cap file; Syngene International Limited: National Stock Exchange of India, daily market-cap file; Belite Bio, Inc: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CG Oncology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Oruka Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Immunovant, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Alkermes plc.: How market caps are worked out; Rhythm Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Biocon Limited———
Syngene International Limited———
Belite Bio, Inc———
CG Oncology, Inc.———
Oruka Therapeutics, Inc.———
Immunovant, Inc.———
Alkermes plc.17.2%FY2025
85th percentile in Healthcaremedian -8.0%, 684 companies
74th percentile in Irelandmedian 9.3%, 25 companies
Rhythm Pharmaceuticals, Inc.-101.2%FY2025
23rd percentile in Healthcaremedian -8.0%, 684 companies
10th percentile in USAmedian 3.5%, 2,595 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$416 M$832 M$1.2 B$1.7 B20112013201520172019202120232025CG Oncology, Inc. $4 MAlkermes plc. $1.5 BRhythm Pharmaceuticals, Inc. $190 M

Rank in the group

1st2nd3rd20212022202320242025CG Oncology, Inc.: 3rd of 3 in 2023CG Oncology, Inc.: 3rd of 3 in 2024CG Oncology, Inc.: 3rd of 3 in 2025CG Oncology, Inc.Alkermes plc.: 1st of 2 in 2021Alkermes plc.: 1st of 2 in 2022Alkermes plc.: 1st of 3 in 2023Alkermes plc.: 1st of 3 in 2024Alkermes plc.: 1st of 3 in 2025Alkermes plc.Rhythm Pharmaceuticals, Inc.: 2nd of 2 in 2021Rhythm Pharmaceuticals, Inc.: 2nd of 2 in 2022Rhythm Pharmaceuticals, Inc.: 2nd of 3 in 2023Rhythm Pharmaceuticals, Inc.: 2nd of 3 in 2024Rhythm Pharmaceuticals, Inc.: 2nd of 3 in 2025Rhythm Pharmaceuticals, In
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearBiocon LimitedSyngene International LimitedBelite Bio, IncCG Oncology, Inc.Oruka Therapeutics, Inc.Immunovant, Inc.Alkermes plc.Rhythm Pharmaceuticals, Inc.
2025———$4 MSEC3rd——$1.5 BSEC1st$190 MSEC2nd
2024———$1 MSEC3rd——$1.6 BSEC1st$130 MSEC2nd
2023———$0 MSEC3rd——$1.7 BSEC1st$77 MSEC2nd
2022——————$1.1 BSEC1st$24 MSEC2nd
2021——————$1.2 BSEC1st$3 MSEC2nd
2020——————$1.0 BSEC—
2019——————$1.2 BSEC—
2018——————$1.1 BSEC—
2017——————$903 MSEC—
2016——————$746 MSEC—
2015——————$628 MSEC—
2014——————$619 MSEC—

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Biocon Limited#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Syngene International LimitedSYNGENE.BO · 🇮🇳 India
    Same industry: Biotechnology · Similar size: $2.0 B market cap against $6.4 B · Same country: India
    Market cap $2.0 B (Nov 20, 2026) · revenue $388 M (year to March 2023)
    87 of 100 (industry or sector 50 + size 22 + country 15)
    In the group
  • Belite Bio, IncBLTE · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $6.4 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $6.4 B (Aug 1, 2026)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • CG Oncology, Inc.CGON · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $6.6 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $6.6 B (Sep 24, 2026) · revenue $4 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Oruka Therapeutics, Inc.ORKA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $6.5 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $6.5 B (Oct 28, 2026)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Immunovant, Inc.IMVT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $6.6 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $6.6 B (Oct 7, 2026)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Alkermes plc.ALKS · 🇮🇪 Ireland
    Same industry: Biotechnology · Similar size: $6.7 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $6.7 B (Oct 14, 2026) · revenue $1.5 B (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Rhythm Pharmaceuticals, Inc.RYTM · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $6.0 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $6.0 B (Oct 15, 2026) · revenue $190 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Ligand Pharmaceuticals IncorporatedLGND · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $5.9 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $5.9 B (Oct 20, 2026) · revenue $268 M (year to December 2025)
    84 of 100 (industry or sector 50 + size 30 + figures on file 5)
    + Add
  • Ionis Pharmaceuticals, Inc.IONS · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $7.1 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $7.1 B (Oct 26, 2026) · revenue $944 M (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    + Add
  • Kodiak Sciences Inc.KOD · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $5.7 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $5.7 B (Oct 22, 2026)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    + Add
  • Kiniksa Pharmaceuticals, Ltd.KNSA · 🇧🇲 Bermuda
    Same industry: Biotechnology · Similar size: $7.5 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $7.5 B (Oct 29, 2026) · revenue $678 M (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    + Add
  • Cogent Biosciences, Inc.COGT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $5.5 B market cap against $6.4 B · Ratios of the last two fiscal years on file
    Market cap $5.5 B (Oct 22, 2026)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.